Clinical Trial Update: Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and dosimetry of the radiopharmaceutical [18F]GEH121224 in locally advanced or metastatic breast cancer has been withdrawn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• [18F]GEH121224 (GEH121224)

Snippet

Sponsor: GE Healthcare | Conditions: Breast Cancer | Phase 1 | Status: WITHDRAWN